RSS Feed Print
A Brain-Deliverable, Anti-Amyloid Antibody
Posted: Tuesday, May 8, 2012 1:24 PM
Joined: 12/6/2011
Posts: 3326

From Alzheimer's Daily News:

(Source: SYS-CON Media) - BiOasis Technologies announced test results of its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain.

The results demonstrate that Transcend can increase considerably the delivery of an anti-amyloid beta antibody (anti-AB) to the brain.


One of the challenges facing companies currently testing anti-AB antibodies in clinical trials for the treatment of Alzheimer's disease (AD) is getting enough of the antibody to cross the blood-brain barrier and into the brain. The passive immunization of AD patients using antibodies directed at the AB peptide is a potential therapeutic strategy aimed at reducing amyloid plaques in the brain. The plaques, consisting of insoluble amyloid B protein are thought to be responsible for the neuronal cell death and the associated cognitive impairment seen in AD patients. Approaches that can efficiently deliver these antibodies into the brain may be the key for their use in the treatment of AD.


"As we reported earlier, a number of pharmaceutical companies are in early and late stage clinical trials studying anti-AB antibodies as potential treatments for AD. biOasis has shown over the past several months that its Transcend Vector can deliver antibodies ... and other large and small molecules across the blood-brain barrier to achieve higher concentrations than those seen with the effector molecules on their own." said Rob Hutchison, CEO.


Go to full story: